Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2018

12.01.2018 | Melanomas

Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and Lower-Risk Tumors

verfasst von: Serigne N. Lo, PhD, Richard A. Scolyer, MD, John F. Thompson, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Counterintuitively, more deaths from melanoma occur among patients with thin (T1) primary melanomas (≤ 1 mm) than among those with thick primary melanoma because the great majority present with T1 tumors. Therefore, it is important to stratify their risk as accurately as possible to guide their management and follow-up. This study sought to explore the relationship between tumor thickness and prognosis for patients with thin primary melanomas.

Methods

A retrospective, single-institution study investigated 6263 patients with cutaneous melanoma (including 2117 T1 cases) who had a minimum follow-up period of 10 years.

Results

For the entire patient cohort, the 10-year melanoma-specific survival (MSS) rate ranged between 92% for the patients with primary melanomas up to 0.3 mm thick and 32% for those with melanomas thicker than 8 mm. When divided into 25-quantile-thickness groups there was a significant difference in 10-year MSS between the two consecutive groups 0.8 and 0.9 mm; the differences in survival were not significantly different for any other consecutive cut points within the less than or equal to 1 mm thickness range, indicating a biologically-relevant difference in outcome above and below 0.8 mm. For the patients treated initially at the authors’ institution, the 10- and 20-year MSS rates for those with tumors up to 0.8 mm thick were respectively 93.4 and 85.7%, and for tumors 0.9 to 1.0 mm, the rates were respectively 81.1 and 71.4%. Only 29.3% of the T1 patients who died of melanoma were deceased within 5 years.

Conclusions

A naturally occurring thickness cut point of 0.8 mm predicts higher or lower risk for patients with thin primary cutaneous melanomas. Long-term follow-up assessment of patients with T1 melanoma is important because late mortality due to melanoma is more common than early mortality.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.CrossRefPubMedPubMedCentral Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Balch CM, Soong SJ, Shaw HM, Milton GW. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, editors. Cutaneous melanoma: clinical management and treatment results worldwide. 2nd ed. JB Lipincott, Philadelphia, 1992, pp. 165–187. Balch CM, Soong SJ, Shaw HM, Milton GW. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, editors. Cutaneous melanoma: clinical management and treatment results worldwide. 2nd ed. JB Lipincott, Philadelphia, 1992, pp. 165–187.
4.
Zurück zum Zitat Garbe C, Buttner P, Bertz J, Burg G, d’Hoedt B, Drepper H, et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer. 1995;75:2484–91.CrossRefPubMed Garbe C, Buttner P, Bertz J, Burg G, d’Hoedt B, Drepper H, et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer. 1995;75:2484–91.CrossRefPubMed
5.
Zurück zum Zitat Masback A, Olsson H, Westerdahl J, Ingvar C, Jonsson N. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res. 2001;11:435–45.CrossRefPubMed Masback A, Olsson H, Westerdahl J, Ingvar C, Jonsson N. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res. 2001;11:435–45.CrossRefPubMed
6.
Zurück zum Zitat Scolyer RA, Judge MJ, Evans A, Frishberg DP, Prieto VG, Thompson JF, et al, International collaboration on cancer R. Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol. 2013;37:1797–814.CrossRefPubMedPubMedCentral Scolyer RA, Judge MJ, Evans A, Frishberg DP, Prieto VG, Thompson JF, et al, International collaboration on cancer R. Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol. 2013;37:1797–814.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Buettner P, Garbe C, Guggenmoos-Holzmann I. Problems in defining cutoff points of continuous prognostic factors: example of tumor thickness in primary cutaneous melanoma. J Clin Epidemiol. 1997;50:1201–10.CrossRefPubMed Buettner P, Garbe C, Guggenmoos-Holzmann I. Problems in defining cutoff points of continuous prognostic factors: example of tumor thickness in primary cutaneous melanoma. J Clin Epidemiol. 1997;50:1201–10.CrossRefPubMed
8.
Zurück zum Zitat Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129–34.CrossRefPubMed Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129–34.CrossRefPubMed
9.
Zurück zum Zitat Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg. 2003;238:528–35.PubMedPubMedCentral Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg. 2003;238:528–35.PubMedPubMedCentral
10.
Zurück zum Zitat Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using “optimal” cut points in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829–35.CrossRefPubMed Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using “optimal” cut points in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829–35.CrossRefPubMed
11.
Zurück zum Zitat Contal C, O’Quigley J. An application of change-point methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal. 1999;30:253–70.CrossRef Contal C, O’Quigley J. An application of change-point methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal. 1999;30:253–70.CrossRef
12.
Zurück zum Zitat Faraggi D, Simon R. A simulation study of cross-validation for selecting an optimal cut point in univariate survival analysis. Stat Med. 1996;15:2203–13.CrossRefPubMed Faraggi D, Simon R. A simulation study of cross-validation for selecting an optimal cut point in univariate survival analysis. Stat Med. 1996;15:2203–13.CrossRefPubMed
13.
Zurück zum Zitat Hilsenbeck SG, Clark GM. Practical p value adjustment for optimally selected cut points. Stat Med. 1996;15:103–12.CrossRefPubMed Hilsenbeck SG, Clark GM. Practical p value adjustment for optimally selected cut points. Stat Med. 1996;15:103–12.CrossRefPubMed
14.
Zurück zum Zitat Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat. 1992;22:197–206.CrossRefPubMed Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat. 1992;22:197–206.CrossRefPubMed
15.
Zurück zum Zitat Amin MB, Edge SB, Greene FL, Carducci MA, Compton CA, editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing: 2017. Amin MB, Edge SB, Greene FL, Carducci MA, Compton CA, editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing: 2017.
16.
Zurück zum Zitat Cumming G, Finch S. Inference by eye: confidence intervals and how to read pictures of data. Am Psychol. 2005;60:170–80.CrossRefPubMed Cumming G, Finch S. Inference by eye: confidence intervals and how to read pictures of data. Am Psychol. 2005;60:170–80.CrossRefPubMed
17.
Zurück zum Zitat Woodward M. Epidemiology: study design and data analysis. 2nd ed. Boca Raton: Chapman and Hall/CRC Press; 2005. Woodward M. Epidemiology: study design and data analysis. 2nd ed. Boca Raton: Chapman and Hall/CRC Press; 2005.
18.
Zurück zum Zitat Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67:472–92. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017;67:472–92.
19.
Zurück zum Zitat Green AC, Baade P, Coory M, Aitken JF, Smithers M. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012;30:1462–7.CrossRefPubMed Green AC, Baade P, Coory M, Aitken JF, Smithers M. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012;30:1462–7.CrossRefPubMed
20.
Zurück zum Zitat Mansson-Brahme E, Carstensen J, Erhardt K, Lagerlof B, Ringborg U, Rutqvist LE. Prognostic factors in thin cutaneous malignant melanoma. Cancer. 1994;73:2324–32.CrossRefPubMed Mansson-Brahme E, Carstensen J, Erhardt K, Lagerlof B, Ringborg U, Rutqvist LE. Prognostic factors in thin cutaneous malignant melanoma. Cancer. 1994;73:2324–32.CrossRefPubMed
21.
Zurück zum Zitat Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45:3012–7.CrossRefPubMed Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45:3012–7.CrossRefPubMed
22.
Zurück zum Zitat McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003;98:1223–31.CrossRefPubMed McKinnon JG, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003;98:1223–31.CrossRefPubMed
23.
Zurück zum Zitat Shaw HM, McCarthy WH, McCarthy SW, Milton GW. Thin malignant melanomas and recurrence potential. Arch Surg. 1987;122:1147–50.CrossRefPubMed Shaw HM, McCarthy WH, McCarthy SW, Milton GW. Thin malignant melanomas and recurrence potential. Arch Surg. 1987;122:1147–50.CrossRefPubMed
24.
Zurück zum Zitat Yonick DV, Ballo RM, Kahn E, Dahiya M, Yao K, Godellas C, et al. Predictors of positive sentinel lymph node in thin melanoma. Am J Surg. 2011;201:324–7.CrossRefPubMed Yonick DV, Ballo RM, Kahn E, Dahiya M, Yao K, Godellas C, et al. Predictors of positive sentinel lymph node in thin melanoma. Am J Surg. 2011;201:324–7.CrossRefPubMed
25.
Zurück zum Zitat Keefe M, Mackie RM. The relationship between risk of death from clinical stage 1 cutaneous melanoma and thickness of primary tumour: no evidence for steps in risk. Br J Cancer. 1991;64:598–602.CrossRefPubMedPubMedCentral Keefe M, Mackie RM. The relationship between risk of death from clinical stage 1 cutaneous melanoma and thickness of primary tumour: no evidence for steps in risk. Br J Cancer. 1991;64:598–602.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Clark WH Jr, From L, Bernardino EA, et al. The histogenesis and biological behavior of primary human malignant melanoma of the skin. Cancer Res. 1969;29:705–27.PubMed Clark WH Jr, From L, Bernardino EA, et al. The histogenesis and biological behavior of primary human malignant melanoma of the skin. Cancer Res. 1969;29:705–27.PubMed
27.
Zurück zum Zitat Scolyer R, Shaw H, Thompson J, Li L, Colman M, Lo S, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571–6.CrossRefPubMed Scolyer R, Shaw H, Thompson J, Li L, Colman M, Lo S, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571–6.CrossRefPubMed
28.
Zurück zum Zitat Murali R, Hughes M, FitzGerald P, Thompson J, Scolyer R. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly Clark level, affects pathologic staging of primary cutaneous melanoma. Ann Surg. 2009;249:641–7.CrossRefPubMed Murali R, Hughes M, FitzGerald P, Thompson J, Scolyer R. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly Clark level, affects pathologic staging of primary cutaneous melanoma. Ann Surg. 2009;249:641–7.CrossRefPubMed
29.
Zurück zum Zitat Braun RP, Gutkowicz-Krusin D, Rabinovitz H, Cognetta A, Hofmann-Wellenhof R, Ahlgrimm-Siess V, et al. Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the “gold standard”? Dermatology. 2012;224:51–8.CrossRefPubMed Braun RP, Gutkowicz-Krusin D, Rabinovitz H, Cognetta A, Hofmann-Wellenhof R, Ahlgrimm-Siess V, et al. Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the “gold standard”? Dermatology. 2012;224:51–8.CrossRefPubMed
30.
Zurück zum Zitat Glusac EJ. The melanoma “epidemic”: lessons from prostate cancer. J Cutan Pathol. 2012;39:17–20.CrossRefPubMed Glusac EJ. The melanoma “epidemic”: lessons from prostate cancer. J Cutan Pathol. 2012;39:17–20.CrossRefPubMed
31.
Zurück zum Zitat Mihic-Probst D, Shea C, Duncan L, de la Fouchardiere A, Landman G, Landsberg J, et al. Update on thin melanoma: outcome of an international workshop. Adv Anat Pathol. 2016;23:24–9.CrossRefPubMed Mihic-Probst D, Shea C, Duncan L, de la Fouchardiere A, Landman G, Landsberg J, et al. Update on thin melanoma: outcome of an international workshop. Adv Anat Pathol. 2016;23:24–9.CrossRefPubMed
32.
Zurück zum Zitat Monheit G, Cognetta AB, Ferris L, Rabinovitz H, Gross K, Martini M, et al. The performance of MelaFind: a prospective multicenter study. Arch Dermatol. 2011;147:188–94.CrossRefPubMed Monheit G, Cognetta AB, Ferris L, Rabinovitz H, Gross K, Martini M, et al. The performance of MelaFind: a prospective multicenter study. Arch Dermatol. 2011;147:188–94.CrossRefPubMed
Metadaten
Titel
Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates Higher-Risk and Lower-Risk Tumors
verfasst von
Serigne N. Lo, PhD
Richard A. Scolyer, MD
John F. Thompson, MD
Publikationsdatum
12.01.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6325-1

Weitere Artikel der Ausgabe 4/2018

Annals of Surgical Oncology 4/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.